Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Ourperform Rating at Wedbush

Regulus Therapeutics Inc. (NASDAQ:RGLS)‘s stock had its “ourperform” rating reiterated by investment analysts at Wedbush in a report released on Monday. They presently have a $4.00 price target on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 329.65% from the stock’s previous close.

RGLS has been the subject of a number of other reports. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Wednesday, July 12th. BMO Capital Markets set a $1.00 price objective on Regulus Therapeutics and gave the stock a “hold” rating in a report on Monday, June 12th. ValuEngine cut Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Chardan Capital cut Regulus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $3.58.

Regulus Therapeutics (NASDAQ:RGLS) traded up 3.0397% during trading on Monday, reaching $0.9593. The company’s stock had a trading volume of 84,223 shares. The company’s market cap is $51.02 million. Regulus Therapeutics has a 52-week low of $0.86 and a 52-week high of $3.82. The stock has a 50-day moving average price of $1.00 and a 200 day moving average price of $1.35.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.10. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. On average, analysts expect that Regulus Therapeutics will post ($1.06) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Ourperform Rating at Wedbush” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.com-unik.info/2017/08/07/regulus-therapeutics-inc-nasdaqrgls-given-ourperform-rating-at-wedbush.html.

In related news, Director William H. Rastetter bought 274,725 shares of the stock in a transaction dated Tuesday, July 25th. The stock was bought at an average price of $0.91 per share, with a total value of $249,999.75. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Joseph P. Hagan bought 219,780 shares of the stock in a transaction dated Tuesday, July 25th. The stock was bought at an average cost of $0.91 per share, with a total value of $199,999.80. Following the purchase, the insider now owns 241,297 shares in the company, valued at approximately $219,580.27. The disclosure for this purchase can be found here. In the last three months, insiders bought 549,450 shares of company stock valued at $500,000. 4.80% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in RGLS. Wells Fargo & Company MN raised its stake in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 93,295 shares during the period. South Dakota Investment Council raised its stake in Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock worth $2,190,000 after buying an additional 186,130 shares during the period. Teachers Advisors LLC raised its stake in Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 9,804 shares during the period. Wedbush Securities Inc. raised its stake in Regulus Therapeutics by 106.8% in the first quarter. Wedbush Securities Inc. now owns 180,921 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 93,420 shares during the period. Finally, Tudor Investment Corp ET AL raised its stake in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 61,373 shares during the period. 21.09% of the stock is owned by institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

What are top analysts saying about Regulus Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regulus Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit